Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 323 | 45 | 276 |
| Samples | 187 | 33 | 153 |
| Peptides | 154 | 26 | 132 |
Function
RGR · Retinal G protein coupled receptor
This gene encodes a putative retinal G-protein coupled receptor. The gene is a member of the opsin subfamily of the 7 transmembrane, G-protein coupled receptor 1 family. Like other opsins which bind retinaldehyde, it contains a conserved lysine residue in the seventh transmembrane domain. The protein acts as a photoisomerase to catalyze the conversion of all-trans-retinal to 11-cis-retinal. The reverse isomerization occurs with rhodopsin in retinal photoreceptor cells. The protein is exclusively expressed in tissue adjacent to retinal photoreceptor cells, the retinal pigment epithelium and Mueller cells. This gene may be associated with autosomal recessive and autosomal dominant retinitis pigmentosa (arRP and adRP, respectively). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 124 amino-acid changes on canonical ENST00000359452 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RGR · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RGR – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Hodgkins Lymphoma | 4/16 25% | 0/122 0% |
| Endometrial Carcinoma | 0/42 0% | 9/612 1% |
| Melanoma | 4/210 2% | 22/1899 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 12/1390 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 6/810 1% |
| Bladder Carcinoma | 2/58 3% | 7/956 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Other Solid Cancers | 0/94 0% | 9/1515 1% |
| Gastric Carcinoma | 2/74 3% | 8/1809 0% |
| Colorectal Carcinoma | 4/143 3% | 14/3239 0% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| Wilms Tumour | 0/5 0% | 1/474 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 5/2640 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Ovarian Carcinoma | 2/109 2% | 0/998 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 3/2534 0% |
Mutation Distribution
Where RGR is mutated · all tissues, split by cell line vs tissue
How many mutations in RGR were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 43 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 323 mutations in RGR
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|